Treatment options for patients with advanced cancer are seriously limited. Selective immune attack provides a means to combat disseminated disease. CD40-CD40L interactions have been demonstrated to be critical in the generation of optimal immune responses. We have recently demonstrated that CD40 stimulation using an agonist antibody combined with IL2 can result in highly synergistic anti-tumor responses in mice bearing advanced metastatic renal cell carcinomas (RCC) and other solid tumors. Significant protection occurred using the combination only. This protection was correlated with significant increases in dendritic cell and tumor-specific CD8+ T cell numbers and surprisingly, independent of CD4+ T cell responses. We now propose to delineate the mechanisms underlying these synergistic anti-tumor responses and optimize them. Toward this goal we have developed three specific aims.
Specific Aim 1 will determine the effects of CD40 stimulation on the tumor itself. While CD40 stimulation has been shown to induce activation-induced cell death (AICD) on a variety of B cell lymphomas, the effect on solid tumors is controversial and much less clear. Preliminary data indicate that CD40 stimulation can indeed induce AICD in RCC lines and importantly, may increase susceptibility of the tumor to immune-mediated attack. Assessment of the effects of CD40 stimulation at both cellular and molecular levels will be performed.
Specific Aim 2 will examine the mechanisms as to why there is no engagement of CD4+ T cells after combination treatment and how this may impair sustained anti- tumor responses. Preliminary data suggest that the CD4+ T cell undergo AICD after combination treatment due to interferon-gamma resulting in impaired secondary responses. Means to prevent this CD4+ T cell loss with subsequent effects on anti-tumor responses will be examined. Finally, Specific Aim 3 will determine the efficacy of tumor vaccines and removal of inhibitory influences such as regulatory T cells in advanced tumor-bearing mice. Preliminary data indicates that use of tumor vaccines at the time of anti-CD40 and IL-2 treatment greatly augments efficacy resulting in long-term cures. This proposal should yield significant insights, not only in the clinical extrapolation of CD40 stimulation with IL-2, but also in general immune regulation and tumor responses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA095572-10S1
Application #
8653250
Study Section
Program Officer
Mccarthy, Susan A
Project Start
2012-09-01
Project End
2018-01-31
Budget Start
2013-08-01
Budget End
2014-01-31
Support Year
10
Fiscal Year
2013
Total Cost
$39,322
Indirect Cost
$9,264
Name
University of California Davis
Department
Dermatology
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Monjazeb, Arta M; Tietze, Julia K; Grossenbacher, Steven K et al. (2014) Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help. PLoS One 9:e102709
Mirsoian, Annie; Bouchlaka, Myriam N; Sckisel, Gail D et al. (2014) Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J Exp Med 211:2373-83
Sckisel, Gail D; Tietze, Julia K; Zamora, Anthony E et al. (2014) Influenza infection results in local expansion of memory CD8(+) T cells with antigen non-specific phenotype and function. Clin Exp Immunol 175:79-91
Bouchlaka, Myriam N; Sckisel, Gail D; Chen, Mingyi et al. (2013) Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med 210:2223-37
Tietze, Julia K; Wilkins, Danice E C; Sckisel, Gail D et al. (2012) Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood 119:3073-83
Weiss, Jonathan M; Ridnour, Lisa A; Back, Tim et al. (2010) Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med 207:2455-67
Weiss, Jonathan M; Back, Timothy C; Scarzello, Anthony J et al. (2009) Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A 106:19455-60
Alderson, Kory L; Murphy, William J (2009) Effects of cancer immunotherapy regimens on primary vs. secondary immune responses and the potential impact on long-term antitumor responses. Adv Exp Med Biol 633:81-9
Puliaev, Roman; Puliaeva, Irina; Welniak, Lisbeth A et al. (2008) CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus. J Immunol 181:47-61
Alderson, Kory L; Zhou, Qing; Berner, Vanessa et al. (2008) Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy. J Immunol 180:2981-8

Showing the most recent 10 out of 19 publications